@article {Knopman10.1212 / WNL。0000000000207438,作者= {David Knopman和琳达好},title = {Lecanemab批准的影响阿尔茨海默病病人护理:增量步范式转变},elocation-id = {10.1212 / WNL。={2023}0000000000207438},年,doi = {10.1212 / WNL。出版商0000000000207438}= {Wolters Kluwer健康,公司代表美国神经病学学会},抽象={淀粉样蛋白级联模型的阿尔茨海默病(AD)的发病机理是wellsupported半岛投注体育官网观察性研究。其治疗推论断言删除amyloid-β肽({\ textquotedblleft} {\ textquotedblright})淀粉样蛋白能提供临床医学方面的好处。经过20年的追求淀粉样蛋白去除没有成功的策略,种抗体单克隆抗体的临床试验(AAMA) donanemab和lecanemab报道的3期临床试验的临床好处与淀粉样蛋白去除。Lecanemab(贸易名称,LeqembiTM)是唯一一个与发表的3期临床试验的结果。每两周进行静脉注射时升高脑淀粉样蛋白和轻度认知障碍患者或轻度痴呆,lecanemab认知和功能恶化推迟了大约五个月的18个月的双盲,安慰剂对照试验。这次审判是品行端正的,结果支持lecanemab内部一致。lecanemab延迟治疗的临床进展的示威游行的人轻微症状由于广告是一个重要的概念上的成就,但更好的升值幅度和耐久性给每位患者的利益需要扩展从临床实践观察设置。淀粉样蛋白相关的成像异常(咏叹调),主要是无症状发生在大约20 \ %,略超过一半是由底层AD-related淀粉样血管病治疗和休息。 Persons who were homozygous for the APOE e4 allele had greater ARIA risks. Hemorrhagic complications with longer term lecanemab use need to be better understood. Administration of lecanemab will place unprecedented pressures on dementia care personnel and infrastructure, both of which need to grow exponentially to meet the challenge.}, issn = {0028-3878}, URL = {//www.ebmtp.com/content/early/2023/06/09/WNL.0000000000207438}, eprint = {//www.ebmtp.com/content/early/2023/06/09/WNL.0000000000207438.full.pdf}, journal = {Neurology} }